Physician profile
David B Duncan
NPI 1053364430
$130,421.10
in general payments reported to CMS, 2019-2025
45 companies · $4,344 in 2025
The $4,344 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $24K · 2021: $21K · 2022: $20K · 2023: $16K · 2024: $6,206 · 2025: $4,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $6,551 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,212 · Travel and Lodging: $211 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,656.36 |
| Food and Beverage | $6,551.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,212.00 |
| Travel and Lodging | $211.06 |
| Education | $117.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $25,369.34 | 2019-2025 | Zeposia |
| Genzyme Corporation | $19,365.40 | 2019-2025 | |
| Emd Serono, INC. | $19,013.37 | 2019-2025 | Evobrutinib, Mavenclad |
| Genentech USA, INC. | $19,002.88 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Biogen, INC. | $17,773.02 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| E.R. Squibb & Sons, L.L.C. | $15,860.49 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $4,997.86 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $2,043.42 | 2020-2025 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $1,929.66 | 2023-2025 | |
| Janssen Global Services, LLC | $1,700.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $563.90 | 2020-2023 | Ponvory |
| Horizon Therapeutics Plc | $336.76 | 2021-2023 | Uplizna |
| Amgen INC. | $334.45 | 2024-2025 | Uplizna |
| Allergan, INC. | $275.01 | 2019-2022 | |
| Genentech, INC. | $206.74 | 2020-2024 | Ocrevus, Ocrevus Zunovo |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viz.Ai, INC. | $170.49 | 2022 | |
| Ani Pharmaceuticals, INC. | $135.34 | 2024-2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $116.09 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $114.33 | 2019 | |
| Abbvie INC. | $103.54 | 2022-2025 | Ubrelvy, Qulipta |
| Novocure INC. | $97.06 | 2023 | Optune |
| Teva Pharmaceuticals USA, INC. | $86.97 | 2019-2023 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $81.66 | 2024-2025 | Ponvory |
| Lundbeck LLC | $77.31 | 2022-2024 | Vyepti |
| Philips North America LLC | $71.58 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $70.25 | 2019-2022 | |
| Medtronic USA, INC. | $70.04 | 2019 | |
| Acorda Therapeutics, INC | $58.73 | 2019-2024 | Ampyra |
| Bayer Healthcare Pharmaceuticals INC. | $52.22 | 2019 | |
| Bioventus LLC | $48.97 | 2024 | Bonescalpel & Sonicone (O.R.) |
| Mallinckrodt Hospital Products INC. | $48.49 | 2020-2022 | |
| Lilly USA, LLC | $40.15 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $34.01 | 2023 | Nuedexta |
| Medtronic, INC. | $25.11 | 2023 | Intellis Adaptivestim |
| Cycle Pharmaceuticals INC | $16.97 | 2025 | Tascenso Odt |
| Pfizer INC. | $16.96 | 2023 | |
| Ucb, INC. | $16.19 | 2024 | Fintepla |
| Banner Life Sciences, LLC | $15.66 | 2024 | |
| Axsome Therapeutics, INC. | $15.00 | 2022 | |
| Merck Sharp & Dohme LLC | $14.70 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.10 | 2019 | |
| Harmony Biosciences LLC | $13.30 | 2022 | |
| Eisai INC. | $12.75 | 2021 | |
| Arbor Pharmaceuticals, INC. | $10.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.